QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT

NCT07327788 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Hepatecellular Carcinoma
RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin
Bevacizumab
Type VP3/4 Portal Vein Tumor Thrombosis
Iparomlimab and Tuvonralimab Injection
QL1706

Interventions

DRUG: Iparomlimab and Tuvonralimab Injection (QL1706)
DRUG: Bevacizumab
PROCEDURE: Hepatic Arterial Infusion Chemotherapy with Raltitrexed and Oxaliplatin (RALOX-HAIC)

Sponsor

Nanfang Hospital, Southern Medical University